Change on the Repeatable Battery for the Assessment of Neuropsychological Status and its relationship to brain amyloid.

Autor: Duff K; Layton Aging and Alzheimer's Disease Center, Department of Neurology, Oregon Health & Science University, Portland, OR, United States.; Center for Alzheimer's Care, Imaging and Research, Department of Neurology, University of Utah, Salt Lake City, UT, United States., Dixon AM; Center for Alzheimer's Care, Imaging and Research, Department of Neurology, University of Utah, Salt Lake City, UT, United States., Embree L; Center for Alzheimer's Care, Imaging and Research, Department of Neurology, University of Utah, Salt Lake City, UT, United States., Hoffman JM; Center for Quantitative Cancer Imaging, Huntsman Cancer Institute, Salt Lake City, UT, USA.; Department of Radiology and Imaging Sciences, University of Utah, Salt Lake City, UT, United States.
Jazyk: angličtina
Zdroj: Journal of clinical and experimental neuropsychology [J Clin Exp Neuropsychol] 2023 Mar; Vol. 45 (2), pp. 105-117. Date of Electronic Publication: 2023 May 24.
DOI: 10.1080/13803395.2023.2216920
Abstrakt: Background: The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) has been associated with commonly used biomarkers of Alzheimer's disease (AD), including brain amyloid plaque density. However, less is known about if changes in the RBANS across time are also related to brain amyloid deposition. The current study sought to expand on prior work by examining the relationship between changes over time on the RBANS and amyloid deposition via positron emission tomography (PET).
Method: One-hundred twenty-six older adults with intact or impaired cognition and daily functioning underwent repeat assessment with the RBANS across nearly 16 months, as well as had a baseline amyloid PET scan.
Results: In the entire sample, amyloid deposition was significantly related to change on all five Indexes and the Total Scale score of the RBANS, with greater amyloid being associated with worsening cognition. This pattern was also observed in 11 of 12 subtests.
Conclusions: Whereas prior studies have identified a relationship between baseline RBANS and amyloid status, the current findings support that changes in the RBANS are also indicative of AD brain pathology, even if these findings are mediated by cognitive status. Although replication in a more diverse sample is needed, these results continue to support the use of the RBANS in AD clinical trials.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje